HK1205751A1 - 共軛物、顆粒、組合物及相關方法 - Google Patents

共軛物、顆粒、組合物及相關方法

Info

Publication number
HK1205751A1
HK1205751A1 HK15106196.2A HK15106196A HK1205751A1 HK 1205751 A1 HK1205751 A1 HK 1205751A1 HK 15106196 A HK15106196 A HK 15106196A HK 1205751 A1 HK1205751 A1 HK 1205751A1
Authority
HK
Hong Kong
Prior art keywords
conjugates
compositions
particles
related methods
methods
Prior art date
Application number
HK15106196.2A
Other languages
English (en)
Inventor
Scott Eliasof
Oliver S Fetzer
Jungyeon Hwang
Patrick Lim Soo
Pei-Sze Ng
Sonke Svenson
Donald Bergstrom
Original Assignee
Cerulean Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerulean Pharma Inc filed Critical Cerulean Pharma Inc
Publication of HK1205751A1 publication Critical patent/HK1205751A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK15106196.2A 2012-02-22 2015-06-30 共軛物、顆粒、組合物及相關方法 HK1205751A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261601944P 2012-02-22 2012-02-22
US201261636180P 2012-04-20 2012-04-20
US201261650825P 2012-05-23 2012-05-23
US201261718603P 2012-10-25 2012-10-25

Publications (1)

Publication Number Publication Date
HK1205751A1 true HK1205751A1 (zh) 2015-12-24

Family

ID=49006198

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106196.2A HK1205751A1 (zh) 2012-02-22 2015-06-30 共軛物、顆粒、組合物及相關方法

Country Status (4)

Country Link
US (1) US20140037573A1 (zh)
EP (1) EP2817345A1 (zh)
HK (1) HK1205751A1 (zh)
WO (1) WO2013126564A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2707251C2 (ru) 2011-10-03 2019-11-25 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドModernaTX,Inc. 化学修飾mRNA
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015094928A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Liposomal compositions for allosteric akt inhibitors
WO2015184326A1 (en) * 2014-05-30 2015-12-03 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
AU2015280417B2 (en) 2014-06-24 2020-01-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
CN104906075B (zh) * 2015-06-19 2017-07-11 中国药科大学 共递送纳米载体及其制备方法
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
JP2019504027A (ja) * 2015-12-22 2019-02-14 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティThe Trustees Of Princeton University 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
DK3394030T3 (da) 2015-12-22 2022-03-28 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af midler
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
KR20190132405A (ko) 2017-03-15 2019-11-27 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 화합물 및 조성물
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US10482365B1 (en) * 2017-11-21 2019-11-19 Wells Fargo Bank, N.A. Transaction instrument containing metal inclusions
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
AU2021231914A1 (en) * 2020-03-06 2022-11-03 Endolytix Technology, Inc. Compositions and methods for the treatment of intracellular bacterial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
CA2652280C (en) * 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2010021770A1 (en) * 2008-08-22 2010-02-25 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
EP2413901A4 (en) * 2009-03-30 2015-05-06 Cerulean Pharma Inc POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
US20130017167A1 (en) * 2009-11-13 2013-01-17 University Of Washington Through Its Center For Commercialization Hydrophobic block conjugated therapeutic agents

Also Published As

Publication number Publication date
US20140037573A1 (en) 2014-02-06
EP2817345A1 (en) 2014-12-31
WO2013126564A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
HK1205751A1 (zh) 共軛物、顆粒、組合物及相關方法
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
EP2605799A4 (en) CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS
IL252566B (en) Pharmacy preparations and methods
EP2809345A4 (en) IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
ZA201405694B (en) Virus like particle composition
HK1210913A1 (zh) 粒子、方法以及其用途
EP2885318A4 (en) PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
HK1204970A1 (zh) 聚合物劑型共扼物、顆粒、組合物及其使用的相關方法
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
EP2912069A4 (en) GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS AND RELATED METHODS
SG11201405261TA (en) Bio-polyols for bio-lubricant and bio-polymer and methods for the preparation thereof
HK1206970A1 (zh) 抗原組合物及方法
EP2852602A4 (en) COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
EP2892511A4 (en) BOLAAMPHIPHILE COMPOUNDS, COMPOSITIONS AND USES THEREOF
EP2892512A4 (en) BOLAAMPHIPHILE COMPOUNDS, COMPOSITIONS AND USES THEREOF
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
EP2834635A4 (en) COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR